Gillian F. Black,1‡* Bonnie A. Thiel,2‡ Martin O. Ota,3 Shreemanta K. Parida,4 Richard Adegbola,3 W. Henry Boom,2,5 Hazel M. Dockrell,6 Kees L. M. C. Franken,7 Annemiek H. Friggen,7 Philip C. Hill,3§ Michel R. Klein,7¶ Maeve K. Lalor,6 Harriet Mayanja,5 Gary Schoolnik,8 Kim Stanley,1 Karin Weldingh,9  Stefan H. E. Kaufmann,4 Gerhard Walzl,1 Tom H. M. Ottenhoff,7 and the GCGH Biomarkers for TB Consortium Department of Biomedical Sciences, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa1; Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, Ohio2; Bacterial Diseases Programme, Medical Research Council, P.O. Box 273, Banjul, The Gambia3; Department of Immunology, Max Planck Institute for Infection Biology, D-10117 Berlin, Germany4; Department of Medicine, Makerere University, Kampala, Uganda5; Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, United Kingdom6; Department of Immunohematology and Blood Transfusion, and Department of Infectious Diseases, Leiden University Medical Centre, NL-2300 RC Leiden, The Netherlands7; Department of Microbiology and Immunology, Stanford University, Stanford, California8; and Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark9

Download this file (496_Black_CVI_2009.pdf)496_Black_CVI_2009.pdf[ ]621 kB

The dose of efavirenz during concomitant rifampin (RMP) administration is a matter of debate. We studied the influence of RMP coadministration on the steady-state pharmacokinetics of efavirenz in human immunodeficiency virus type 1 (HIV-1)-infected patients in South India. Fifty-seven HIV-tuberculosis (TB)-coinfected and 15 HIV-1-infected patients receiving combination antiretroviral therapy (CART) with an efavirenz (600 mg once daily)-containing regimen were recruited. HIV-TB-coinfected patients were receiving treatment with RMP-containing regimens. A complete pharmacokinetic study was conducted with 19 HIV-TB patients on two occasions (with and without RMP).

Molecular surveillance of multidrug-resistant tuberculosis (MDR TB) was implemented in Europe as case reporting in 2005. For all new MDR TB cases detected from January 2003 through June 2007, countries reported case-based epidemiologic data and DNA fingerprint patterns of MDR TB strains when available. International clusters were detected and analyzed. From 2003 through mid-2007 in Europe, 2,494 cases of MDR TB were  reported from 24 European countries. Epidemiologic and molecular data were linked for 593 (39%) cases, and 672 insertion sequence 6110 DNA fingerprint patterns were reported from 19 countries.

Urban Sester1, Heinrike Wilkens2, Kai van Bentum1, Mahavir Singh3, Gerhard W. Sybrecht2, Hans-Joachim Schäfers4, and Martina Sester1

1Department of Internal Medicine IV, 2Department of Internal Medicine V, 3Helmholtz Center for Infection Research, and Lionex GmbH, Inhoffenstraße 7, D-38124 Braunschweig, Germany, 4Department of thoracic and cardiovascular surgery, University of the Saarland, D-66421 Homburg, Germany

Short title: TB immunity on immunosuppression

Download this file (466_PUB_ART_Sester_ERJ_2009.pdf)466_PUB_ART_Sester_ERJ_2009.pdf[ ]363 kB

Karen R. Steingart, Nandini Dendukuri, Megan Henry, Ian Schiller, Payam Nahid, Philip C. Hopewell, Andrew Ramsay, Madhukar Pai, and Suman Laal

Received 26 September 2008/Returned for modification 4 November 2008/Accepted 24 November 2008

Serological antibody detection tests for tuberculosis may offer the potential to improve diagnosis. Recent metaanalyses have shown that commercially available tests have variable accuracies and a limited clinical role. We reviewed the immunodiagnostic potential of antigens evaluated in research laboratories (in-house) for the serodiagnosis of pulmonary tuberculosis and conducted a meta-analysis to evaluate the performance of comparable antigens.

Sobre a REDE-TB

A Rede Brasileira de Pesquisa em Tuberculose (REDE-TB) é uma Organização Não Governamental (ONG) de direito privado sem fins lucrativos, preocupada em auxiliar no desenvolvimento não só de novos medicamentos, novas vacinas, novos testes diagnósticos e novas estratégias de controle de TB, mas também na validação dessas inovações tecnológicas, antes de sua comercialização no país e/ou de sua implementação nos Programa de Controle de TB no País.




Tel: +55 (21)3938 - 2426
Tel/ Fax: +55 (21)3938 - 2431.

Endereço: Avenida Carlos Chagas Filho, 791, Cidade Universitária - Ilha do Fundão, Rio de Janeiro, RJ - Brasil. CEP: 21941-904

Assine a newsletter da REDE-TB

Curta REDE-TB no Facebook